Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ranganathan Ram

Psychiatry Wilmington, DE Medical Doctor

NPI 1003846163 CMS profile 181732

410 Foulk Rd Ste 106, Wilmington, DE 19803

Open in the dashboard

General payments

$201,840

509 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ranganathan Ram of Wilmington, DE is reported in the CMS Open Payments database as having received $201,840 across 509 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $152 2
2023 General $131 2
2021 General $43,371 93
2020 General $17,740 90
2019 General $140,428 321

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ranganathan Ram
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ranganathan Ram were reported at $18. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ranganathan Ram Psychiatry median Middle half National median
2019 $140,428 $184 $59–$605 $163
2020 $17,740 $119 $36–$372 $114
2021 $43,371 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $131 $170 $56–$651 $160
2024 $152 $179 $57–$673 $164
2025 $18 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $164,776 319 payments
  2. Janssen Pharmaceuticals, Inc $34,562 57 payments
  3. Bausch Health US, LLC $591 52 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $329 1 payment
  5. Sunovion Pharmaceuticals Inc. $317 16 payments
  6. Lundbeck LLC $210 13 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $149 9 payments
  8. Axsome Therapeutics, Inc. $128 2 payments
  9. Alkermes, Inc. $120 1 payment
  10. Jazz Pharmaceuticals Inc. $87 5 payments
  11. Other $572 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $163,321 69 payments
  2. Travel and Lodging $29,977 153 payments
  3. Food and Beverage $7,242 285 payments
  4. Consulting Fee $1,296 1 payment
  5. Education $4 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $117,088 238 payments
  2. ABILIFY MAINTENA $50,895 98 payments
  3. SPRAVATO $34,535 55 payments
  4. APLENZIN $591 52 payments
  5. LATUDA $317 16 payments
  6. WELLBUTRIN Neurology $310 31 payments
  7. WELLBUTRIN Neurology $257 19 payments
  8. REXULTI Psychiatry $150 9 payments
  9. Auvelity $128 2 payments
  10. ARISTADA INITIO $120 1 payment
  11. Other $1,547 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

630

Median for Psychiatry & Neurology: 100

Drug cost

$31,001

Median for Psychiatry & Neurology: $2,986

Branded share of claims

20.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 11 $15,230
Trintellix Vortioxetine Hydrobromide Brand 13 $6,175
Venlafaxine Hcl Er Venlafaxine Hcl Brand 16 $1,708
Duloxetine Hcl Generic 59 $1,266
Alprazolam Generic 112 $858
Bupropion Xl Bupropion Hcl Brand 53 $813
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 23 $752
Escitalopram Oxalate Generic 43 $747
Lamotrigine Generic 38 $523
Clonazepam Generic 35 $384

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $152
$152 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

509 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record